Medicare To Track Transfusions In Dialysis Patients To Ensure Appropriate ESA Use
This article was originally published in The Pink Sheet Daily
CMS proposes to monitor transfusions in patients with end-stage renal disease as a new Medicare quality measure aimed at ensuring erythropoiesis-stimulating agents like Amgen’s Epogen are not “underutilized.”
You may also be interested in...
A study from the U.S. Renal Data System contributes to concerns that decreasing use of erythropoiesis-stimulating agents like Amgen’s Epogen in dialysis patients can lead to a significant increase in the need for blood transfusions.
Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.
Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.